TOPEKA, Kan. — As concerns over medication affordability grow, several states are taking measures to regulate pharmacy benefit managers (PBMs), companies that play a significant role in prescription drug pricing and coverage. Prominent among these companies is CVS, which has invested heavily in opposing regulations aimed at curbing their influence.
Legislators in over a dozen states have enacted laws intended to limit PBM compensation, establish minimum payments for pharmacists, and increase transparency to consumers and the public. For instance, a new law in Tennessee will prohibit PBMs from owning retail pharmacies starting in July 2028. CVS has responded with a federal lawsuit challenging this law, arguing it constitutes unfair protectionism for independent pharmacies.
Public sentiment on prescription costs reveals that about 60% of adults are concerned about their ability to afford medications, with a notable proportion admitting to altering their prescriptions due to cost. Despite facing pushback, PBMs argue their role is critical in lowering drug prices by negotiating discounts from pharmaceutical manufacturers. Prem Shah, a CVS executive, expressed that blaming PBMs for high drug prices is misguided, likening their presence to an umbrella in the rain.
This year, more than 120 bills targeting PBMs have emerged in 26 states, with varying degrees of legislative success. Critics of PBMs highlight the potential impact on independent pharmacies and consumers, especially in rural areas where access to medications may be compromised if independent pharmacies struggle to remain profitable amid PBM reimbursements.
While attempts at state-level regulation continue, some experts suggest that comprehensive reform may ultimately need to come from federal legislation, as Congress has recently introduced measures restricting PBM practices, a pivotal step in reshaping the landscape of prescription drug management.
Why this story matters:
- It highlights efforts to make medications more affordable for consumers.
Key takeaway:
- States are increasingly regulating pharmacy benefit managers to address rising drug costs and ensure better access to medications.
Opposing viewpoint:
- Critics argue that limiting PBMs could inadvertently increase prescription costs and negatively impact consumer access to pharmacies.
